Shire to resume marketing of Adderall XR

Share this article:

Shire Pharmaceuticals said that Canadian regulators have approved the company's request to resume marketing Adderall XR in that country.
Health Canada suspended sales of Adderall XR, Shire's biggest product, in February amid concerns the ADHD drug could cause sudden death in some patients. Shire quickly appealed the decision.
The regulatory agency reversed its decision on the advice of its New Drug Committee, which conducted a review of Adderall, Shire said.
With global sales of $607 million last year, Adderall accounts for more than half of Shire's total sales and profit.
Following Canada's withdrawal of Adderall XR, the U.S. FDA worked with Shire to add a warning to the drug's label not to use it in children or adults with heart defects.

 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.